Most SRSF2-wild-type AML samples showed only modest sensitivity to the CHK1 inhibitor prexasertib (median DSS = 11; range 0.2–28), which was markedly lower than in the SRSF2-mutant samples. This evidence concerns the gene SRSF2 and acute myeloid leukemia.